AXNX · Insider Trading
Axonex AI Group Limited Class A Ordinary Shares
Every open-market purchase and sale reported by AXNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-15 | Jane E Kiernan | Director | D | −19,861 | −$1.41M |
| 2024-11-15 | Raymond W Cohen | Chief Executive Officer | D | −292,731 | −$20.78M |
| 2024-11-15 | Kari Leigh Keese | Chief Financial Officer | D | −40,362 | −$2.87M |
| 2024-11-15 | nancy lynn MD snyderman | Director | D | −14,944 | −$1.06M |
| 2024-11-15 | Alfred J Ford Jr | Chief Commercial Officer | D | −43,450 | −$3.08M |
| 2024-11-15 | Robert McNamara | Director | D | −14,861 | −$1.06M |
| 2024-11-15 | John Woock | EVP, Chief Mktg/Strtgy Officer | D | −77,403 | −$5.50M |
| 2024-11-15 | Rinda Sama | Chief Operating Officer | D | −84,462 | −$6.00M |
| 2024-11-15 | Karen Noblett | Chief Medical Officer | D | −34,428 | −$2.44M |
| 2024-11-15 | Michael H Carrel | Director | D | −17,861 | −$1.27M |
| 2024-11-15 | Esteban Lopez | Director | D | −6,600 | −$468.60K |
| 2024-11-15 | David M Demski | Director | D | −9,542 | −$677.48K |
| 2024-11-12 | nancy lynn MD snyderman | Director | G | −5,000 | — |
| 2024-10-03 | Kari Leigh Keese | Chief Financial Officer | Sell | −2,961 | −$205.51K |
| 2024-07-25 | Raymond W Cohen | Chief Executive Officer | M | +103,896 | +$2.38M |
| 2024-02-02 | Alfred J Ford Jr | Chief Commercial Officer | MIXED | +8,885 | −$1.13M |
| 2024-02-02 | Kari Leigh Keese | Chief Financial Officer | MIXED | +2,678 | −$236.33K |
| 2024-02-02 | Rinda Sama | Chief Operating Officer | M | +28,000 | — |
| 2024-02-02 | Raymond W Cohen | Chief Executive Officer | MIXED | +28,239 | −$2.38M |
| 2024-02-02 | John Woock | EVP, Chief Mktg/Strtgy Officer | MIXED | +12,101 | −$1.08M |
| 2024-02-02 | Karen Noblett | Chief Medical Officer | MIXED | +16,212 | −$764.60K |
| 2024-01-10 | Karen Noblett | Chief Medical Officer | Sell | −15,999 | −$1.10M |
| 2023-12-28 | Karen Noblett | Chief Medical Officer | Sell | −8,000 | −$505.96K |
| 2023-10-03 | Danny L. Dearen | President & CFO | MIXED | +18,235 | −$901.54K |
| 2023-10-03 | Danny L. Dearen | President & CFO | MIXED | +3,575 | −$436.49K |
| 2023-08-17 | Alfred J Ford Jr | Chief Commercial Officer | Sell | −14,769 | −$920.67K |
| 2023-08-08 | Michael H Carrel | Director | G | −500 | — |
| 2023-08-01 | Alfred J Ford Jr | Chief Commercial Officer | Sell | −1,500 | −$93.02K |
| 2023-06-28 | Jane E Kiernan | Director | A | +3,000 | — |
| 2023-06-28 | Esteban Lopez | Director | A | +3,000 | — |
| 2023-06-28 | Michael H Carrel | Director | A | +3,000 | — |
| 2023-06-28 | nancy lynn MD snyderman | Director | A | +3,000 | — |
| 2023-06-28 | Robert McNamara | Director | A | +3,000 | — |
| 2023-06-28 | David M Demski | Director | A | +3,000 | — |
| 2023-05-31 | Danny L. Dearen | President & CFO | Sell | −7,999 | −$395.65K |
| 2023-04-25 | Danny L. Dearen | President & CFO | MIXED | −6,792 | −$1.02M |
| 2023-04-24 | Danny L. Dearen | President & CFO | MIXED | — | −$91.68K |
| 2023-04-04 | Danny L. Dearen | President & CFO | MIXED | — | −$589.07K |
| 2023-02-23 | Rinda Sama | Chief Operating Officer | Sell | −23,321 | −$1.31M |
| 2023-02-02 | Rinda Sama | Chief Operating Officer | MIXED | +21,125 | −$1.13M |
| 2023-02-02 | Alfred J Ford Jr | Chief Commercial Officer | MIXED | +14,061 | −$606.98K |
| 2023-02-02 | John Woock | EVP, Chief Mktg/Strtgy Officer | MIXED | +19,326 | −$705.30K |
| 2023-02-02 | Karen Noblett | Chief Medical Officer | MIXED | +10,616 | −$283.16K |
| 2023-02-02 | Danny L. Dearen | President & CFO | MIXED | +16,493 | −$840.60K |
| 2023-02-02 | Raymond W Cohen | Chief Executive Officer | MIXED | +51,697 | −$1.90M |
| 2023-01-19 | John Woock | EVP, Chief Mktg/Strtgy Officer | MIXED | — | −$1.51M |
| 2023-01-18 | Raymond W Cohen | Chief Executive Officer | Sell | −40,736 | −$2.69M |
| 2023-01-18 | Alfred J Ford Jr | Chief Commercial Officer | MIXED | — | −$1.90M |
| 2022-12-15 | Esteban Lopez | Director | Sell | −2,000 | −$134.84K |
| 2022-09-20 | Karen Noblett | Chief Medical Officer | MIXED | — | −$1.92M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AXNX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.